New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
10:26 EDTLM, CNQ, TGT, MSFT, JNS, CQP, APAM, AYI, BIDU, WLH, STI, M, IRWD, BMY, ANF, ATK, AVY, VTR, QLIK, LRY, INCY, BBRYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abercrombie & Fitch (ANF) upgraded to Buy from Neutral at Janney Capital... Artisan Partners (APAM) upgraded to Buy from Neutral at Goldman... BlackBerry (BBRY) upgraded to Sector Perform from Underperform at RBC Capital... Bristol-Myers (BMY) upgraded to Overweight from Equal Weight at Barclays... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Citigroup... Incyte (INCY) upgraded to Overweight from Equal Weight at Barclays... Ironwood (IRWD) upgraded to Outperform from Market Perform at BMO Capital... Janus Capital (JNS) upgraded to Neutral from Sell at Goldman... Liberty Property (LRY) upgraded to Buy from Neutral at UBS... Macy's (M) upgraded to Buy from Neutral at Goldman... Microsoft (MSFT) upgraded to Overweight from Equal Weight at Barclays... Qlik Technologies (QLIK) upgraded to Buy from Hold at Jefferies... SunTrust (STI) upgraded to Conviction Buy from Buy at Goldman... Target (TGT) upgraded to Buy from Neutral at Goldman... Ventas (VTR) upgraded to Buy from Neutral at UBS... William Lyon Homes (WLH) upgraded to Overweight from Neutral at JPMorgan... Canadian Natural (CNQ) upgraded to Outperform from Market Perform at BMO Capital... Avery Dennison (AVY) upgraded at Topeka... Baidu (BIDU) upgraded to Buy from Hold at Maxim... ATK (ATK) upgraded to Buy from Hold at Argus... Legg Mason (LM) upgraded to Neutral from Negative at Susquehanna... Acuity Brands (AYI) upgraded to Neutral from Underperform at Wedbush.
News For ANF;APAM;BBRY;BMY;CQP;INCY;IRWD;JNS;LRY;M;MSFT;QLIK;STI;TGT;VTR;WLH;CNQ;AVY;BIDU;LM;ATK;AYI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
July 21, 2015
11:11 EDTMSFTMicrosoft technical notes before earnings, levels to watch
On a long-term basis the stock has a potential double top pattern that would be confirmed on a breakdown below $40. In a shorter time frame the stock is range-bound between $45 at the low and $50 at the high. If the news is bearish, a breakdown below $45 would put the shares on a path for a test at that $40 support. A breakdown below $40 would see next support at $39.27 and then at $38.56. The downside target from the double top would be to the $30 area over time. If the news is a bullish surprise, a breakout above $50 would see next resistance at $53.13 and then at $55. Both are levels not seen since the year 2000.
10:01 EDTAPAMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ASML (ASML) upgraded to Accumulate from Neutral at SNS Securities... Anacor (ANAC) upgraded to Buy from Neutral at Goldman... Artisan Partners (APAM) upgraded to Outperform from Neutral at Credit Suisse... Canadian National (CNI) upgraded to Buy from Hold at Canaccord... General Mills (GIS) upgraded to Outperform from Sector Perform at RBC Capital... Halliburton (HAL) upgraded to Accumulate from Neutral at Global Hunter... Harte-Hanks (HHS) upgraded to Outperform from Market Perform at BMO Capital... MDC Partners (MDCA) upgraded to Overweight from Neutral at Piper Jaffray... SABMiller (SBMRY) upgraded to Buy from Neutral at Nomura... Sanmina (SANM) upgraded to Neutral from Underperform at Longbow... Santander Mexico (BSMX) upgraded to Neutral from Sell at Goldman... Sherwin-Williams (SHW) upgraded to Buy from Neutral at Northcoast... Southwestern Energy (SWN) upgraded to Buy from Neutral at Global Hunter... Verisk Analytics (VRSK) assumed with an Outperform at Keefe Bruyette.
09:56 EDTMSFTSalesforce rallies amid renewed speculation of Microsoft deal
Subscribe for More Information
09:02 EDTBMYBristol-Myers Squibb receives FDA breakthrough designation for HIV-1 inhibitor
Bristol-Myers Squibb announced that the FDA has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral, or ARV, agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients. BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. The attachment inhibitor is designed to work differently than entry inhibitors, a current class of drugs that targets co-receptorsí activity or fusion after HIV attaches to the CD4+ host cell. BMS-663068 is thought to work at an earlier point in the replication process to prevent the virusí initial interaction with immune cells entirely, and thus blocks its entry into the cell.
07:04 EDTMSFTMicrosoft July weekly volatility elevated into Q4 and outlook
Subscribe for More Information
06:17 EDTAPAMArtisan Partners upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse upgraded Artisan Partners to Outperform and increased its price target to $57 from $50. The firm believes Q2 flows improved by $2B and expects a positive inflection during Q3. Credit Suisse raised organic growth forecasts to 4%-5% and said its high active share business and DOL Rule compliant fund structures will drive market shares gains.
July 20, 2015
16:01 EDTMSFTOptions Update; July 20, 2015
Subscribe for More Information
14:12 EDTQLIKQlik Technologies channel checks suggest incremental strength, says BofA/Merrill
BofA/Merrill's channel checks indicate incremental strength in new customer activity for Qlik Sense. The firm rates Qlik Technologies a Buy and raised its price target to $45 from $40 heading into Thursday's report based on C16 sales multiple.
13:46 EDTTGT, MAmazon seen eclipsing Macy's as top U.S. clothing retailer
Subscribe for More Information
12:09 EDTBMYBristol-Myers says Nivolumab BMS approved in EU for SQ NSCLC
Subscribe for More Information
12:08 EDTBMYOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday in the first trading day of a week that will be light on domestic economic data but heavy on earnings reports. Investors will be receiving profit reports from about 25% of the companies on the S&P 500 this week, making this the highest volume earnings week of this season. ECONOMIC EVENTS: In the U.S., no major data was released. In Europe, Greece reopened its banks three weeks after closing as the country worked out another bailout agreement. The country announced it has started the process of paying off its creditors, including the European Central Bank and the International Monetary Fund, with a bridge loan it just received. COMPANY NEWS: Lockheed Martin (LMT) agreed to buy the Sikorsky Aircraft business from United Technologies (UTX) for $9B, noting the price is "effectively reduced" to $7.1B after taking into account tax benefits resulting from the transaction. Shares of Lockheed, which also reported better than expected second quarter results and increased its fiscal year guidance, gained nearly 2% after the Sikorsky announcement and saying it will conduct a strategic review of its government IT infrastructure services business and technical services business... Shares of Morgan Stanley (MS) shares were little changed near noon after the bank reported earnings and revenue, excluding certain adjustments, that topped analysts' consensus forecasts... SunEdison (SUNE) announced a deal to acquire Vivint Solar (VSLR) for approximately $2.2B, payable in a combination of cash, shares of SunEdison common stock and SunEdison convertible notes. In connection with the proposed acquisition of Vivint Solar, SunEdison has entered into a definitive purchase agreement with a subsidiary of TerraForm Power (TERP) which, concurrently with the completion of SunEdison's acquisition of Vivint, will acquire Vivint Solar's rooftop solar portfolio, consisting of 523 MW expected to be installed by year-end 2015, for $922M in cash. Shares of Vivint rose 44% following the announcement, while SunEdison's stock gained 4% and TerraForm dropped 3%. Fellow residential solar installer SolarCity (SCTY), which is backed by Tesla's (TSLA) Elon Musk, rose 7% following the deal in the space. MAJOR MOVERS: Among the notable gainers was Exelixis (EXEL), which rallied 43% after the company reported that a study of cabozantinib in metastatic renal cell carcinoma met its primary endpoint of significant improvement in progression-free survival. The shares were indicated to rise even more in early pre-market trading, but lost some of their gains after Bristol-Myers (BMY) announced that its Opdivo study was stopped early after showing superior overall survival in a Phase 3 study of previously treated patients with advanced or metastatic renal cell carcinoma. Bristol-Myers rose a bit less than 1% to trade near $70 per share after its own announcement. Also higher was PayPal (PYPL), which gained more than 5.5% in its first day of trading after being spun out of eBay (EBAY). Meanwhile, eBay shares rose over 2%. Cal-Maine Foods (CALM) dropped 8% after posting lower than expected sales and profits in its fourth quarter and warning that while it should have an adequate supply of its primary feed ingredients, the company expects that prices will be "volatile" in the year ahead. Also lower were shares of several gold miners, including Barrick Gold (ABX) and Newmont Mining (NEM), which each fell about 11%, as gold prices declined about 2% near midday. INDEXES: Near midday, the Dow was up 31.66, or 0.18%, to 18,118.11, the Nasdaq was up 9.81, or 0.19%, to 5,219.96, and the S&P 500 was up 2.82, or 0.13%, to 2,129.46.
10:00 EDTSTIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:04 EDTMSFTGE chooses Microsoft Office 365 fro employee collaboration and productivity
Subscribe for More Information
08:28 EDTBMYExelixis off highs, but still up 34% after Bristol-Myers data
Subscribe for More Information
08:08 EDTMMacy's price target to $78 on likelihood of a REIT transaction at BofA/Merrill
Subscribe for More Information
08:05 EDTBMYBristol-Myers says Phase III study evaluating Opdivo stopped early
Subscribe for More Information
07:33 EDTBMYInternational AIDS Society to hold a conference
Subscribe for More Information
06:26 EDTSTISunTrust downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
July 19, 2015
19:04 EDTMSFTMicrosoft to buy Adallom for $320M, Globes says
Microsoft has agreed to acquire cyber security firm Adallom for roughly $320M, reports Globes, without naming sources. Reference Link
18:13 EDTM, TGTMacy's considered, rejected sale/lease-backs in past, WSJ says
Macy's (M) executives have considered sale/lease-backs "over the years" and have come to negative conclusions, reports the Wall Street Journal, citing people familiar with the company. The report comes in the wake of Starboard Value pressuring Macy's to spin off its real estate, and sources said the activist investor sees several options, including a REIT, a Hudsonís Bayís-style real estate partnership, a sale/lease-back, or borrowing money against the properties. Separately, a source said Target (T) is still reluctant to relinquish control over its real estate. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use